Role of radiopharmaceuticals in the diagnosis and treatment of neuroendocrine tumours

Eur J Cancer. 2009 Sep:45 Suppl 1:274-91. doi: 10.1016/S0959-8049(09)70042-5.

Authors

Irene J Virgolini¹, Michael Gabriel, Elisabeth von Guggenberg, Daniel Putzer, Dorota Kendler, Clemens Decristoforo

Affiliation

¹ Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria.

PMID: 19775625
DOI: 10.1016/S0959-8049(09)70042-5

No abstract available

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Disease Progression
Forecasting
Hematologic Diseases / chemically induced
Humans
Kidney Failure, Chronic / chemically induced
Neuroendocrine Tumors* / diagnostic imaging
Neuroendocrine Tumors* / drug therapy
Neuroendocrine Tumors* / radiotherapy
Patient Selection
Peptides
Positron-Emission Tomography / methods
Quality of Life
Radiopharmaceuticals* / therapeutic use
Radiotherapy Dosage
Receptors, Peptide / antagonists & inhibitors
Receptors, Peptide / radiation effects
Receptors, Somatostatin / antagonists & inhibitors
Receptors, Somatostatin / radiation effects
Treatment Outcome

Substances

Peptides
Radiopharmaceuticals
Receptors, Peptide
Receptors, Somatostatin